Research progress of hypothyroidism and atherosclerosis

Home > Archive>Volume 29, Issue 6, 2021 >489-493

Research progress of hypothyroidism and atherosclerosis
DOI:
                        
                    
CSTR:
                        [cstr]
                    
Author:
                        YANG YunxiaoYANG Yunxiao
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
ZHANG MingZHANG Ming
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China)
Clc Number:
Fund Project:

Article

Figures

Metrics

Reference [46]

Related [20]

Cited by

Materials

Comments

Reference

[1] JABBAR A, PINGITORE A, PEARCE S H, et al.Thyroid hormones and cardiovascular disease.Nat Rev Cardiol, 7,4(1):39-55.

[2] HAK A E, POLS H A, VISSER T J, et al.Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women:the rotterdam study.Ann Intern Med, 0,2(4):270-278.

[3] RODONDI N, DEN ELZEN W P, BAUER D C, et al.Subclinical hypothyroidism and the risk of coronary heart disease and mortality.JAMA, 0,4(12):1365-1374.

[4] NING Y, CHENG Y J, LIU L J, et al.What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1 898 314 participants.BMC Med, 7,5(1):21.

[5] ZHANG M, SARA J D, MATSUZAWA Y, et al.Clinical outcomes of patients with hypothyroidism undergoing percutaneous coronary intervention.Eur Heart J, 6,7(26):2055-2065.

[6] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等.甲状腺功能减退症基层诊疗指南(2019年).中华全科医师杂志, 9,8(11):1022-1028.

[7] CHAKER L, BIANCO A C, JONKLAAS J, et al.Hypothyroidism.Lancet, 7,0(10101):1550-1562.

[8] SAMPSON U K, FAZIO S, LINTON M F.Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins:the evidence, etiology, and therapeutic challenges.Curr Atheroscler Rep, 2,4(1):1-10.

[9] WONG N D, ZHAO Y, QUEK R G W, et al.Residual atherosclerotic cardiovascular disease risk in statin-treated adults:the multi-ethnic study of atherosclerosis.J Clin Lipidol, 7,1(5):1223-1233.

[10] AZIZ M, KANDIMALLA Y, MACHAVARAPU A, et al.Effect of thyroxin treatment on carotid intima-media thickness (CIMT) reduction in patients with subclinical hypothyroidism (sch):a meta-analysis of clinical trials.J Atheroscler Thromb, 7,4(7):643-659.

[11] BLUM M R, GENCER B, ADAM L, et al.Impact of thyroid hormone therapy on atherosclerosis in the elderly with subclinical hypothyroidism:a randomized trial.J Clin Endocrinol Metab, 8,3(8):2988-2997.

[12] MOOIJAART S P, DU PUY R S, STOTT D J, et al.Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism.JAMA, 9,2(20):1-11.

[13] TAYLOR P N, ALBRECHT D, SCHOLZ A, et al.Global epidemiology of hyperthyroidism and hypothyroidism.Nat Rev Endocrinol, 8,4(5):301.

[14] VANDERPUMP M P.The epidemiology of thyroid disease.Br Med Bull, 1,9:39-51.

[15] SHAN Z, CHEN L, LIAN X, et al.Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in china:a cross-sectional study in 10 cities.Thyroid, 6,6(8):1125-1130.

[16] CAPPOLA A R, DESAI A S, MEDICI M, et al.Thyroid and cardiovascular disease research agenda for enhancing knowledge, prevention, and treatment.Circulation, 9,9(6):760-777.

[17] RITTER M J, AMANO I, HOLLENBERG A N.Thyroid hormone signaling and the liver.Hepatology, 0,2(2):742-752.

[18] RAZVI S, JABBAR A, PINGITORE A, et al.Thyroid hormones and cardiovascular function and diseases.J Am Coll Cardiol, 8,1(16):1781-1796.

[19] FAZAELI M, KHOSHDEL A, SHAFIEPOUR M, et al.The influence of subclinical hypothyroidism on serum lipid profile, PCSK9 levels and CD36 expression on monocytes.Diabetes Metab Syndr, 9,3(1):312-316.

[20] BONDE Y, BREUER O, LüTJOHANN D, et al.Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans.J Lipid Res, 4,5(11):2408-2415.

[21] HURTUBISE J, MCLELLAN K, DURR K, et al.The different facets of dyslipidemia and hypertension in atherosclerosis.Curr Atheroscler Rep, 6,8(12):82.

[22] PIANTANIDA E, GALLO D, VERONESI G, et al.Masked hypertension in newly diagnosed hypothyroidism:a pilot study.J Endocrinol Invest, 6,9(10):1131-1138.

[23] KLEIN I, DANZI S.Thyroid disease and the heart.Circulation, 7,6(15):1725-1735.

[24] NAGASAKI T, INABA M, KUMEDA Y, et al.Increased pulse wave velocity in subclinical hypothyroidism.J Clin Endocrinol Metab, 6,1(1):154-158.

[25] CHEN Z, MARTIN M, LI Z, et al.Endothelial dysfunction:the role of sterol regulatory element-binding protein-induced nod-like receptor family pyrin domain-containing protein 3 inflammasome in atherosclerosis.Curr Opin Lipidol, 4,5(5):339-349.

[26] ZHU J, LIU Y, ZHANG Y, et al.VAMP3 and SNAP23 mediate the disturbed flow-induced endothelial microrna secretion and smooth muscle hyperplasia.Proc Natl Acad Sci U S A, 7,4(31):8271-8276.

[27] TADDEI S, CARACCIO N, VIRDIS A, et al.Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism:beneficial effect of levothyroxine therapy.J Clin Endocrinol Metab, 3,8(8):3731-3737.

[28] YANG C, LU M, CHEN W, et al.Thyrotropin aggravates atherosclerosis by promoting macrophage inflammation in plaques.J Exp Med, 9,6(5):1182-1198.

[29] GONG N, GAO C, CHEN X, et al.Endothelial function in patients with subclinical hypothyroidism:a meta-analysis.Horm Metab Res, 9,1(11):691-702.

[30] 杜海梅, 王娜, 张永莉.糖尿病合并亚临床甲状腺功能减退症及其对动脉粥样硬化的影响.中国动脉硬化杂志, 8,6(3):315-320.

[31] TIAN L, ZHANG L, LIU J, et al.Effects of tsh on the function of human umbilical vein endothelial cells.J Mol Endocrinol, 4,2(2):215-222.

[32] BIONDI B, CAPPOLA A R, COOPER D S.Subclinical hypothyroidism:a review.JAMA, 9,2(2):153-160.

[33] 杨云潇, 贾一凡, 黄梦玲, 等.1级亚临床甲状腺功能减退症促甲状腺激素水平与冠状动脉狭窄程度的相关性研究.心肺血管病杂志, 0,9(6):672-675.

[34] BEKKERING G, AGORITSAS T, LYTVYN L, et al.Thyroid hormones treatment for subclinical hypothyroidism:a clinical practice guideline.BMJ, 9,5:l2006.

[35] 宁瑜, 张铭, 杜芸辉, 等.甲状腺激素对氧化型低密度脂蛋白诱导的巨噬细胞功能紊乱的影响.生理学报, 8,0(2):141-148.

[36] VAN DER SPEK A H, FLIERS E, BOELEN A.Thyroid hormone metabolism in innate immune cells.J Endocrinol, 7,2(2):R67-R81.

[37] VAN DER SPEK A H, FLIERS E, BOELEN A.Thyroid hormone and deiodination in innate immune cells.Endocrinology, 2021.DOI:10.1210/endocr/bqaa200.

[38] BILLON C, CANAPLE L, FLEURY S, et al.TRα protects against atherosclerosis in male mice:identification of a novel anti-inflammatory property for TRα in mice.Endocrinology, 4,5(7):2735-2745.

[39] ZHU S, WANG Y, LIU H, et al.Thyroxine affects lipopolysaccharide-induced macrophage differentiation and myocardial cell apoptosis via the NF-κB p65 pathway both in vitro and in vivo .Mediators Inflamm, 9,9:2098972.

[40] VAN DER SPEK A H, SUROVTSEVA O V, JIM K K, et al.Regulation of intracellular triiodothyronine is essential for optimal macrophage function.Endocrinology, 8,9(5):2241-2252.

[41] GROOTAERT M O J, ROTH L, SCHRIJVERS D M, et al.Defective autophagy in atherosclerosis:to die or to senesce.Oxid Med Cell Longev, 8,8:7687083.

[42] SERGIN I, EVANS T D, ZHANG X, et al.Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis.Nat Commun, 7,8:15750.

[43] YANG Y, JIA Y, NING Y, et al.TAK1-AMPK pathway in macrophages regulates hypothyroid atherosclerosis.Cardiovasc Drugs Ther, 2020.DOI:10.1007/s10557-020-06996-w.

[44] DAY E A, FORD R J, STEINBERG G R.AMPK as a therapeutic target for treating metabolic diseases .Trends Endocrinol Metab, 7,8(8):545-560.

[45] WANG J, LI Z, GAO L, et al.The regulation effect of AMPK in immune related diseases.Sci Chin Life Sci, 8,1(5):523-533.

[46] WANG P, XU T Y, GUAN Y F, et al.Vascular smooth muscle cell apoptosis is an early trigger for hypothyroid atherosclerosis.Cardiovasc Res, 4,2(3):448-459.

Get Citation

YANG Yunxiao, ZHANG Ming. Research progress of hypothyroidism and atherosclerosis[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(6):489-493.

Copy

Article Metrics

Abstract:562
PDF: 952
HTML: 0
Cited by: 0

History

Received:November 10,2020
Revised:December 14,2020
Adopted:
Online: June 11,2021
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code